Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 2019

View Archived Issues

Microbiome ineffective at remyelination support

A whole parasite vaccination approach against malaria presented

IBI-315 begins phase I trial in China for HER2-expressing advanced solid malignancies

Anti-CD39 antibody ES-002 demonstrates efficacy in multiple myeloma xenograft model

ZW-25 shows promising single-agent antitumor activity in advanced HER2-expressing cancers

Global phase III study of trastuzumab biosimilar HLX-02 meets primary endpoint

Patient recruitment ongoing in phase I/II study of BTZ-043 in pulmonary tuberculosis

Subcutaneous infliximab biosimilar approved in the E.U. for the treatment of RA

TMAO is associated with diffuse cardiac fibrosis in HIV-positive individuals

Merck KGaA presents phase I data for the novel antimalarial candidate M-5717

Peroxiredoxin-1 as a novel therapeutic target in LPS-induced AKI

Identification of exosomal miRNAs as novel biomarkers and therapeutic targets in ADPKD

AstraZeneca identifies new TRPC3 and TRPC6 antagonists

Imago Biosciences describes new KDM1A inhibitors

G12C-mutant GTPase KRAS inhibitors patented by Amgen

Myungmoon Bio, Kyungpook National University disclose new anticancer compounds

LG Chem discovers new enteropeptidase inhibitors

"Absolutely fascinating": Stem cells, dead cells work equally well for heart repair

iRNA therapy ARO-APOC3 reduces triglycerides in healthy volunteers

Lonza and DiNAQOR collaborate to advance gene therapy programs for monogenic cardiomyopathies

Prokarium receives MHRA clearance to begin first-in-human study of enteric fever vaccine Entervax

Lilly initiates phase II study of LY-3454738 in chronic spontaneous urticaria

Henlius reports phase I data on anti-PD-1 antibody HLX-10 in advanced solid tumors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 23, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.